Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.
Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.
复制标题
DOI：
10.1016/j.oraloncology.2013.06.011
复制
发表时间：
2013-09
期刊：
影响因子：
4.8
通讯作者：
Seshadri, Mukund
中科院分区：
文献类型：
--
作者：
Folaron, Margaret;Kalmuk, James;Lockwood, Jaimee;Frangou, Costakis;Vokes, Jordan;Turowski, Steven G.;Merzianu, Mihai;Rigual, Nestor R.;Sullivan-Nasca, Maureen;Kuriakose, Moni A.;Hicks, Wesley L., Jr.;Singh, Anurag K.;Seshadri, Mukund
The need to improve chemotherapeutic efficacy against head and neck squamous cell carcinomas (HNSCC) is well recognized. In this study, we investigated the potential of targeting the established tumor vasculature in combination with chemotherapy in head and neck cancer. Experimental studies were carried out in multiple human HNSCC xenograft models to examine the activity of the vascular disrupting agent (VDA) 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in combination with chemotherapy. Multimodality imaging (magnetic resonance imaging, bioluminescence) in conjunction with drug delivery assessment (fluorescence microscopy), histopathology and microarray analysis was performed to characterize tumor response to therapy. Long-term treatment outcome was assessed using clinically-relevant end points of efficacy. Pretreatment of tumors with VDA prior to administration of chemotherapy increased intratumoral drug delivery and treatment efficacy. Enhancement of therapeutic efficacy was dependent on the dose and duration of VDA treatment but was independent of the chemotherapeutic agent evaluated. Combination treatment resulted in increased tumor cell kill and improvement in progression-free survival and overall survival in both ectopic and orthotopic HNSCC models. Our results show that preconditioning of the tumor microenvironment with an antivascular agent primes the tumor vasculature and results in enhancement of chemotherapeutic delivery and efficacy in vivo. Further investigation into the activity of antivascular agents in combination with chemotherapy against HNSCC is warranted.
登录
查看更多内容
影响因子：
3.4
作者：
Clemenson, Celine;Jouannot, Erwan;Deutsch, Eric
通讯作者：
Deutsch, Eric
通过与 5-羟色胺和生物还原药物联合使用，增强抗血管剂 5,6-二甲基呫吨酮-4-乙酸 (DMXAA) 的抗肿瘤作用。
影响因子：
8.8
作者：
Lash, C J;Li, A E;Rutland, M;Baguley, B C;Zwi, L J;Wilson, W R
通讯作者：
Wilson, W R
影响因子：
12.3
作者：
Gentleman RC;Carey VJ;Bates DM;Bolstad B;Dettling M;Dudoit S;Ellis B;Gautier L;Ge Y;Gentry J;Hornik K;Hothorn T;Huber W;Iacus S;Irizarry R;Leisch F;Li C;Maechler M;Rossini AJ;Sawitzki G;Smith C;Smyth G;Tierney L;Yang JY;Zhang J
通讯作者：
Zhang J
影响因子：
5.7
作者：
Blanchard, Pierre;Baujat, Bertrand;Pignon, Jean-Pierre
通讯作者：
Pignon, Jean-Pierre
DOI：
10.1016/s0360-3016(02)03920-2
发表时间：
2002-12-01
影响因子：
7
作者：
Baguley, BC;Ching, LM
通讯作者：
Ching, LM